Myrto Moutafi,Georgia-Angeliki Koliou,George Papaxoinis,Panagiota Economopoulou,Ioannis Kotsantis,Maria Gkotzamanidou,Maria Anastasiou,Dimitrios Pectasides,Efthymios Kyrodimos,Alexander Delides,Evangelos Giotakis,Nikolaos G Papadimitriou,Ioannis G Panayiotides,Christos Perisanidis,Aileen I Fernandez,Vasiliki Xirou,Christos Poulios,Eleni Gagari,Vesal Yaghoobi,Niki Gavrielatou,Saba Shafi,Thazin Nwe Aung,Andromachi Kougioumtzopoulou,Vassilis Kouloulias,Konstantinos Palialexis,Stavros Gkolfinopoulos,Areti Strati,Evi Lianidou,George Fountzilas,David L Rimm,Periklis G Foukas,Amanda Psyrri

Abstract:Purpose: We conducted a phase II randomized noncomparative window of opportunity (WOO) trial to evaluate the inhibition of cellular proliferation and the modulation of immune microenvironment after treatment with olaparib alone or in combination with cisplatin or durvalumab in patients with operable head and neck squamous cell carcinoma (HNSCC). Experimental design: Forty-one patients with HNSCC were randomized to cisplatin plus olaparib (arm A), olaparib alone (arm B), no treatment (arm C) or durvalumab plus olaparib (arm D). The primary endpoint was to evaluate the percentage of patients in each arm that achieved a reduction of at least 25% in Ki67. Secondary endpoints included objective response rate (ORR), safety, and pathologic complete response (pCR) rate. Paired baseline and resection tumor biopsies and blood samples were evaluated for prespecified biomarkers. Results: A decrease in Ki67 of at least 25% was observed in 44.8% of treated patients, as measured by quantitative immunofluorescence. The ORR among treated patients was 12.1%. pCR was observed in 2 patients. Two serious adverse events occurred in 2 patients.Programmed death ligand 1 (PD-L1) levels [combined positive score (CPS)] were significantly higher after treatment in arms A and D. Expression of CD163 and colony-stimulating factor 1 receptor (CSF1R) genes, markers of M2 macrophages, increased significantly posttreatment whereas the expression of CD80, a marker of M1 macrophages, decreased. Conclusion: Preoperative olaparib with cisplatin or alone or with durvalumab was safe in the preoperative setting and led to decrease in Ki67 of at least 25% in 44.8% of treated patients. Olaparib-based treatment modulates the tumor microenvironment leading to upregulation of PD-L1 and induction of protumor features of macrophages. Significance: HNSCC is characterized by defective DNA repair pathways and immunosuppressive tumor microenvironment. PARP inhibitors, which promote DNA damage and "reset" the inflammatory tumor microenvironment, can establish an effective antitumor response. This phase II WOO trial in HNSCC demonstrated the immunomodulatory effects of PARP inhibitor-induced DNA damage. In this chemo-naïve population, PARP inhibitor-based treatment, reduced tumor cell proliferation and modulated tumor microenvironment. After olaparib upregulation of PD-L1 and macrophages, suggests that combinatorial treatment might be beneficial. Synopsis: Our WOO study demonstrates that preoperative olaparib results in a reduction in Ki67, upregulation of PD-L1 CPS, and induction of protumor features of macrophages in HNSCC.

The DNA damage response network in the treatment of head and neck squamous cell carcinoma

Data from Integrative Analysis Identifies a Novel AXL–PI3 Kinase–PD-L1 Signaling Axis Associated with Radiation Resistance in Head and Neck Cancer

Characterization of DNA damage repair pathway utilization in high-grade serous ovarian cancers yields rational therapeutic approaches

Targeting DNA damage response as a potential therapeutic strategy for head and neck squamous cell carcinoma

Association between polymorphisms of DNA repair genes and survival of advanced NSCLC patients treated with platinum-based chemotherapy

Are DNA Repair Gene Alterations Associated With the Response to Platinum-Based Regimen and Immune Checkpoint Inhibitors in Patients With Solid Tumors?

Targeting the DNA damage response in hematological malignancies

DNA damage response inhibitors in cancer therapy: lessons from the past, current status and future implications

Targeting DNA damage response pathways in cancer

Advancing cancer therapy: new frontiers in targeting DNA damage response

Ercc1 Immunohistochemical Expression And Cancer-Specific Survival In Patients With Locally Advanced Squamous-Cell Carcinoma Of The Head And Neck Treated By Cisplatin-Based Induction Chemotherapy

Detection of oxaliplatin- and cisplatin-DNA lesions requires different global genome repair mechanisms that affect their clinical efficacy

Targeting DNA Damage Repair for Immune Checkpoint Inhibition: Mechanisms and Potential Clinical Applications

DNA damage response and repair gene mutations are associated with tumor mutational burden and outcomes to platinum-based chemotherapy/immunotherapy in advanced NSCLC patients

DNA damage repair pathway alterations in metastatic clear cell renal cell carcinoma and implications on systemic therapy

Correlation of Homologous Recombination Deficiency in Head and Neck Cancer with Sensitivity to Parp Inhibition

Germline DNA damage response gene mutations as predictive biomarkers of immune checkpoint inhibitor efficacy

Impact of DNA Damage Response and Repair (DDR) Gene Mutations on Efficacy of PD-(L)1 Immune Checkpoint Inhibition in Non-Small Cell Lung Cancer

DNA damage response in breast cancer and its significant role in guiding novel precise therapies

Phase II Window Study of Olaparib Alone or with Cisplatin or Durvalumab in Operable Head and Neck Cancer

Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers.